Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 5:33 PM
Ignite Modification Date:
2025-12-25 @ 3:06 PM
NCT ID:
NCT02315768
Group ID:
EG000
Title:
GA101+Ibrutinib
Description:
Ibrutinib 420 mg (140 mg capsules 3 times) orally once daily for up to 6 cycles.
GA101 (Obinutuzumab) by Intravenous infusion for up to 6 cycles (28 day cycles) as follows:
* Cycle 1, Day 1,100 mg GA101 obinutuzumab will be administered.
* Cycle 1, Day 2, 900 mg of GA101 obinutuzumab will be administered.
* Cycle 1, Days 8 and 15,1,000 mg of GA101 obinutuzumab will be administered.
* Cycles 2-6, Day 1, 1,000 mg of GA101 obinutuzumab will be administered.
GA101
ibrutinib
Deaths Number Affected:
0
Deaths Number At Risk:
None
Serious Number Affected:
3
Serious Number At Risk:
32
Other Number Affected:
32
Other Number At Risk:
32
Study:
NCT02315768
Results Section:
NCT02315768
Adverse Events Module:
NCT02315768